StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
PCVX

Vaxcyte, Inc.

PCVX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗
$53.53
-0.55 -1.02%

Key statistics

from XBRL data in SEC filings
Market cap
$7.73B
Revenue (TTM)
Net income (TTM)
-$181M
EPS (TTM)
$-6.89
P/E ratio
Dividend yield
Free cash flow
-$669M
Cash
$261M
Total assets
$3.35B
Gross margin
52-week range
$29.08 – $65.00

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Director or officer change Jul 15, 2026 8-K Director or officer change Jun 23, 2026 8-K Shareholder vote results Jun 16, 2026 10-Q Quarter ended 2026-03-31 May 6, 2026 8-K Results of operations (earnings release) May 6, 2026 8-K Other events Feb 24, 2026 10-K Fiscal year ended 2025-12-31 Feb 24, 2026 8-K Results of operations (earnings release) Feb 24, 2026 8-K Other events Feb 2, 2026 8-K Director or officer change Dec 19, 2025 10-Q Quarter ended 2025-09-30 Nov 4, 2025 8-K Results of operations (earnings release) Nov 4, 2025 8-K Entered a material agreement Sep 30, 2025 10-Q Quarter ended 2025-06-30 Aug 6, 2025 8-K Results of operations (earnings release) Aug 6, 2025 8-K Shareholder vote results Jun 17, 2025 10-Q Quarter ended 2025-03-31 May 7, 2025 8-K Results of operations (earnings release) May 7, 2025 8-K Director or officer change May 1, 2025 8-K Regulation FD disclosure; Other events Mar 31, 2025 10-K Fiscal year ended 2024-12-31 Feb 25, 2025 8-K Results of operations (earnings release) Feb 25, 2025 8-K Entered a material agreement; Other events Nov 21, 2024 10-Q Quarter ended 2024-09-30 Nov 5, 2024 8-K Results of operations (earnings release) Nov 5, 2024 8-K Other events Sep 6, 2024 8-K Regulation FD disclosure; Other events Sep 3, 2024 10-Q Quarter ended 2024-06-30 Aug 6, 2024 8-K Results of operations (earnings release) Aug 6, 2024 8-K Director or officer change Jul 2, 2024 8-K Shareholder vote results Jun 10, 2024 10-Q Quarter ended 2024-03-31 May 8, 2024 8-K Results of operations (earnings release) May 8, 2024 10-K Fiscal year ended 2023-12-31 Feb 27, 2024 8-K Results of operations (earnings release) Feb 27, 2024 8-K Other events Jan 31, 2024 8-K Director or officer change Nov 28, 2023 8-K Entered a material agreement Nov 27, 2023 10-Q Quarter ended 2023-09-30 Nov 6, 2023 8-K Results of operations (earnings release) Nov 6, 2023